VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials (Q34275084)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

1 August 2017

VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials (English)

1 reference

Europe PubMed Central

1 August 2017

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

9

object named as

Sabine Tejpar

0 references

Eric Van Cutsem

14

object named as

Eric Van Cutsem

0 references

object named as

Paul Delmar

3

0 references

object named as

Joke Reumers

4

0 references

Massimiliano Mazzone

object named as

Massimiliano Mazzone

5

0 references

Diether Lambrechts

1

object named as

Diether Lambrechts

1 reference

Europe PubMed Central

1 August 2017

Peter Carmeliet

12

object named as

Peter Carmeliet

1 reference

Europe PubMed Central

1 August 2017

8

object named as

Chris Verslype

1 reference

Europe PubMed Central

1 August 2017

11

object named as

Sanne de Haas

1 reference

Europe PubMed Central

1 August 2017

author name string

Bart Claes

2

1 reference

Europe PubMed Central

1 August 2017

Betül T Yesilyurt

6

1 reference

Europe PubMed Central

1 August 2017

Roland Devlieger

7

1 reference

Europe PubMed Central

1 August 2017

Hans Wildiers

10

1 reference

Europe PubMed Central

1 August 2017

Stefan J Scherer

13

1 reference

Europe PubMed Central

1 August 2017

publication date

17 May 2012

1 reference

Europe PubMed Central

1 August 2017

number of pages

10

1 reference

based on heuristic

inferred from page(s)

Lancet Oncology Commission

1 reference

Europe PubMed Central

1 August 2017

13

1 reference

Europe PubMed Central

1 August 2017

7

1 reference

Europe PubMed Central

1 August 2017

724-733

1 reference

Europe PubMed Central

1 August 2017

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Kinase targets in renal-cell carcinomas: reassessing the old and discovering the new.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Modes of resistance to anti-angiogenic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Biomarkers to predict the clinical efficacy of bevacizumab in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacogenetic angiogenesis profiling for first-line Bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Vascular endothelial growth factor, its soluble receptor, and hepatocyte growth factor: clinical and genetic correlates and association with vascular function

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Genetic heterogeneity of angiogenesis in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficiency and power in genetic association studies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Optimized filtering reduces the error rate in detecting genomic variants by short-read sequencing.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Identification of vascular endothelial growth factor receptor-1 tyrosine phosphorylation sites and binding of SH2 domain-containing molecules

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Proteases and sFlt-1 release in the human placenta

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Understanding the contribution of synonymous mutations to human disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Preferential codon usage in prokaryotic genes: the optimal codon-anticodon interaction energy and the selective codon usage in efficiently expressed genes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

tRNAdb 2009: compilation of tRNA sequences and tRNA genes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

A role for codon order in translation dynamics.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Bevacizumab and breast cancer: the E2100 outlier

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(12)70231-0

1 reference

Europe PubMed Central

1 August 2017

1 reference

Europe PubMed Central

1 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34275084&oldid=1971493529"